Literature DB >> 34822002

Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment.

Emeline M Aviki1,2, Bridgette Thom3, Kenya Braxton4, Andrew J Chi4, Beryl Manning-Geist4, Fumiko Chino5, Carol L Brown4,6, Nadeem R Abu-Rustum4,6, Francesca M Gany7.   

Abstract

INTRODUCTION: Financial toxicity is common and pervasive among cancer patients. Research suggests that gynecologic cancer patients experiencing financial toxicity are at increased risk for engaging in harmful cost-coping strategies, including delaying/skipping treatment because of costs, or forsaking basic needs to pay medical bills. However, little is known about patients' preferences for interventions to address financial toxicity.
METHODS: Cross-sectional surveys to assess financial toxicity [Comprehensive Score for Financial Toxicity (COST)], cost-coping strategies, and preferences for intervention were conducted in a gynecologic cancer clinic waiting room. Associations with cost-coping were determined using multivariate modeling. Unadjusted odds ratios (ORs) explored associations between financial toxicity and intervention preferences.
RESULTS: Among 89 respondents, median COST score was 31.9 (IQR: 21-38); 35% (N = 30) scored < 26, indicating they were experiencing financial toxicity. Financial toxicity was significantly associated with cost-coping (adjusted OR = 3.32 95% CI: 1.08, 14.34). Intervention preferences included access to transportation vouchers (38%), understanding treatment costs up-front (35%), minimizing wait times (33%), access to free food at appointments (25%), and assistance with minimizing/eliminating insurance deductibles (23%). In unadjusted analyses, respondents experiencing financial toxicity were more likely to select transportation assistance (OR = 2.67, 95% CI: 1.04, 6.90), assistance with co-pays (OR = 9.17, 95% CI: 2.60, 32.26), and assistance with deductibles (OR = 12.20, 95% CI: 3.47, 43.48), than respondents not experiencing financial toxicity.
CONCLUSIONS: Our findings confirm the presence of financial toxicity in gynecologic cancer patients, describe how patients attempt to cope with financial hardship, and provide insight into patients' needs for targeted interventions to mitigate the harm of financial toxicity.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Financial toxicity; Gynecologic cancer; Healthcare costs; Outcomes

Mesh:

Year:  2021        PMID: 34822002      PMCID: PMC9512060          DOI: 10.1007/s00520-021-06697-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  45 in total

Review 1.  A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can't Pay the Co-Pay.

Authors:  Louisa G Gordon; Katharina M D Merollini; Anthony Lowe; Raymond J Chan
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

2.  The financial coping strategies of US cancer patients and survivors.

Authors:  Meredith Doherty; Daniel Gardner; Jackie Finik
Journal:  Support Care Cancer       Date:  2021-03-18       Impact factor: 3.603

3.  Financial toxicity in gynecologic oncology.

Authors:  Sara Bouberhan; Meghan Shea; Alice Kennedy; Adrienne Erlinger; Hannah Stack-Dunnbier; Mary K Buss; Laureen Moss; Kathleen Nolan; Christopher Awtrey; John L Dalrymple; Leslie Garrett; Fong W Liu; Michele R Hacker; Katharine M Esselen
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

4.  The utility of cost discussions between patients with cancer and oncologists.

Authors:  S Yousuf Zafar; Fumiko Chino; Peter A Ubel; Christel Rushing; Gregory Samsa; Ivy Altomare; Jonathan Nicolla; Deborah Schrag; James A Tulsky; Amy P Abernethy; Jeffery M Peppercorn
Journal:  Am J Manag Care       Date:  2015-09       Impact factor: 2.229

5.  Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis.

Authors:  Scott Ramsey; David Blough; Anne Kirchhoff; Karma Kreizenbeck; Catherine Fedorenko; Kyle Snell; Polly Newcomb; William Hollingworth; Karen Overstreet
Journal:  Health Aff (Millwood)       Date:  2013-05-15       Impact factor: 6.301

6.  Dealing with the financial burden of cancer: perspectives of older breast cancer survivors.

Authors:  Maria Pisu; Michelle Y Martin; Richard Shewchuk; Karen Meneses
Journal:  Support Care Cancer       Date:  2014-06-10       Impact factor: 3.603

7.  Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer.

Authors:  Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

8.  Time to add screening for financial hardship as a quality measure?

Authors:  Cathy J Bradley; K Robin Yabroff; S Yousuf Zafar; Ya-Chen Tina Shih
Journal:  CA Cancer J Clin       Date:  2020-11-23       Impact factor: 286.130

Review 9.  Australian Experiences of Out-of-Pocket Costs and Financial Burden Following a Cancer Diagnosis: A Systematic Review.

Authors:  Annie Bygrave; Kate Whittaker; Christine Paul; Elizabeth A Fradgley; Megan Varlow; Sanchia Aranda
Journal:  Int J Environ Res Public Health       Date:  2021-03-02       Impact factor: 3.390

10.  Exploring the role of general practitioners in addressing financial toxicity in cancer patients.

Authors:  Carla Thamm; Jennifer Fox; Nicolas H Hart; Joel Rhee; Bogda Koczwara; Jon Emery; Kristi Milley; Rebecca L Nund; Raymond J Chan
Journal:  Support Care Cancer       Date:  2021-07-26       Impact factor: 3.603

View more
  1 in total

1.  Patient-reported supportive care needs among Asian American cancer patients.

Authors:  Katarina Wang; Carmen Ma; Feng Ming Li; Angeline Truong; Salma Shariff-Marco; Janet N Chu; Debora L Oh; Laura Allen; Mei-Chin Kuo; Ching Wong; Hoan Bui; Junlin Chen; Scarlett L Gomez; Tung T Nguyen; Janice Y Tsoh
Journal:  Support Care Cancer       Date:  2022-08-30       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.